|
WO2020041333A1
|
|
Methods for treating cardiac valve disease
|
|
WO2019245859A1
|
|
Generation of a population of hindbrain cells and hindbrain-like organoids from pluripotent stem cells
|
|
WO2019241435A1
|
|
Compositions for herpesvirus transcriptional feedback circuit disruption and uses thereof
|
|
WO2019200342A1
|
|
Methods for treating apoe4/4-associated disorders
|
|
WO2019099552A1
|
|
Methods of generating retinal pigment epithelium (rpe)
|
|
AU2018313990A1
|
|
Photoreceptor gene modulator photoregulin 3 for treatment of retinal disease
|
|
US2020085797A1
|
|
Compositions And Methods For Reactivating Latent Immunodeficiency Virus Using A Gsk-3 Inhibitor
|
|
WO2018112225A1
|
|
Methods and compositions for generating a deletion library and for identifying a defective interfering particle (dip)
|
|
CA3026621A1
|
|
Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same
|
|
WO2017210138A1
|
|
In vitro methods of differentiating stem cells into neurons and neurons generated using the same
|
|
EP3429567A1
|
|
Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
|
|
EP3402571A1
|
|
Methods of treating disease by metabolic control of t-cell differentiation
|
|
WO2017096161A1
|
|
Compositions and methods for reactivating latent immunodeficiency virus using an akt activator
|
|
EP3332020A1
|
|
Method of determining cellular protein homeostasis
|
|
US9835633B1
|
|
Compositions and methods for identifying agents for treating apoE-related diseases
|
|
US2017360778A1
|
|
Methods for treating a cytomegalovirus infection
|
|
EP3206751A1
|
|
Compositions and methods for reactivating latent immunodeficiency virus
|
|
WO2016007540A2
|
|
Compositions and methods for treating dengue virus infection
|
|
EP3091996A1
|
|
Compositions and methods for in vitro assays of fibrin activity
|
|
US2017003280A1
|
|
In vitro assays for inhibition of microglial activation
|
